CYTOKINETICS INC — Earnings Release 2017

Apr 27, 2017

CoverPageHeader end CoverPageTitle START

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 27, 2017

CoverPageTitle END CoverPageRegistrant START

Cytokinetics, Incorporated ______ (Exact name of registrant as specified in its charter)

Delaware	000-50633	94-3291317
___ (State or other jurisdiction	_______ (Commission	__ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
280 East Grand Avenue, South San Francisco, California		94080
_________ (Address of principal executive offices)		_____ (Zip Code)

Registrant’s telephone number, including area code: (650) 624 - 3000

Not Applicable __________ Former name or former address, if changed since last report

CoverPageRegistrant END

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

PageBreak START

Top of the Form

PageBreak END Item START

Item 2.02 Results of Operations and Financial Condition.

On April 27, 2017, Cytokinetics, Incorporated issued a press release announcing its results for the first quarter ended March 31, 2017. A copy of the press release is being filed as Exhibit 99.1 to this Current Report and is hereby incorporated by reference into this item 2.02.

Item END Item START

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following Exhibits are filed as part of this Current Report on Form 8-K: Exhibit No. Description ---------------------------------- 99.1 Press Release, dated April 27, 2017

Item END

PageBreak START

Top of the Form

PageBreak END SignatureHeader START

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SignatureHeader END Signature START

/s/ Peter S. Roddy
Name: Peter S. Roddy
Title: Senior Vice President, Chief Accounting Officer

Signature END PageBreak START

Top of the Form

PageBreak END

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated April 27, 2017

HTMLFooter START